FDA warning letter · Drugs

Glicerinas Industriales, S.A. de C.V.

Issued · Posted by FDA

Selected passages from the FDA letter

Quoted FDA text from the published dataset. These selected excerpts are not the complete letter.

Passage 1

Failure to test the identity of each batch of incoming production material and appropriately qualify suppliers to rely upon their Certificate of Analysis.

Passage 2

Failure to document, explain, and investigate any deviation from established procedures.

Passage 3

Your firm failed to investigate deviations from your quality specifications for your repackaged drugs. For example, your firm failed to adequately investigate observed contamination of particulates in numerous packaged drugs. According to your production records, the contamination included various unidentified colored particulates, reports of insects, hair, and fibers in your repackaged containers of glycerin, propylene glycol, and **(b)(4)**.